GLP-1 BMI Eligibility 2026: Wegovy and Zepbound

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you searched "GLP-1 BMI calculator" you probably want one number: the Body Mass Index threshold the FDA uses to define eligibility for Wegovy and Zepbound. The labeled answer is consistent across both branded GLP-1s — BMI ≥30, or BMI 27–29.9 with at least one weight-related comorbidity. But that single number isn't the whole story. The branded FDA label is one gate. Insurance coverage criteria are a second, often stricter gate. And the clinical-appropriateness conversation with the prescribing clinician is the third — the one that actually decides whether a GLP-1 lands in your medicine cabinet. This article walks the FDA-labeled BMI thresholds for Wegovy and Zepbound, the comorbidity list that opens the 27–29.9 tier, why the calculator alone won't get you a prescription, and where PlexusDx Semaglutide Injection, Tirzepatide Injection, and the Microdose GLP-1 Protocol sit relative to that branded eligibility frame.

The FDA-labeled BMI thresholds — Wegovy and Zepbound

The two FDA-approved GLP-1 medications indicated for chronic weight management in adults — Wegovy (semaglutide 2.4mg) and Zepbound (tirzepatide) — share an identical labeled eligibility threshold. A patient meets the labeled criteria if they have a BMI of 30 or higher (the obesity threshold), or a BMI of 27–29.9 (the overweight range) accompanied by at least one weight-related comorbidity. Below BMI 27, neither label applies for chronic weight management. Saxenda (liraglutide 3.0mg) uses the same thresholds. These thresholds are pulled directly from the prescribing information for each product and reflect the BMI inclusion criteria used in the pivotal Phase 3 trials — STEP for semaglutide, SURMOUNT for tirzepatide, SCALE for liraglutide. The threshold is conservative because each trial enrolled adults at those BMI ranges; lower-BMI populations weren't studied in the registration program for weight loss. Here's the threshold table at a glance: BMI ≥30, no condition required — meets criteria. BMI 27–29.9 with at least one weight-related condition — meets criteria. BMI 27–29.9 without a weight-related condition — usually doesn't meet labeled criteria. BMI under 27 — below typical thresholds for FDA-labeled weight management indications.

Which weight-related conditions count?

If your BMI is 27–29.9, the comorbidity gate is what determines eligibility. The conditions cited in FDA labeling for the GLP-1 weight management indications include hypertension (high blood pressure), dyslipidemia (high cholesterol, high LDL, low HDL), type 2 diabetes, obstructive sleep apnea, and established cardiovascular disease (prior heart attack, stroke, or documented CVD). Two indications are worth highlighting separately. Wegovy carries a specific FDA indication for cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity — a major-adverse-cardiovascular-event reduction claim from the SELECT trial. Zepbound received an FDA indication in late 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial. You don't need a formal diagnosis on hand to start a telehealth evaluation — the prescribing clinician can document conditions during the consultation if you've been told you have them previously. What you do need is honest information about your medical history and current medications so the clinician can determine clinical appropriateness on top of the labeled BMI criteria.

Why the calculator alone doesn't get you a prescription

BMI eligibility is one of three gates between you and a GLP-1 prescription. The first and most important gate is clinical appropriateness — the prescribing clinician's assessment of contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, history of pancreatitis), drug interactions, and overall safety profile. The second gate is the FDA-labeled criteria the calculator estimates — BMI threshold and comorbidity status. The third gate is insurance coverage. Many commercial insurers apply criteria stricter than FDA labeling for weight-loss GLP-1s — higher BMI cutoffs (e.g., ≥35 or ≥40), required documentation of prior weight-loss attempts, step therapy through cheaper agents first, or category-wide exclusions for anti-obesity medications. As of 2026, most commercial plans still don't cover Wegovy or Zepbound for weight loss without aggressive prior authorization, and Medicare's coverage for weight-loss-only GLP-1 indications remains limited. Meeting BMI criteria is necessary but not sufficient for an insurance-paid prescription. Cash-pay paths sidestep the third gate entirely — which is exactly why PlexusDx Weight Management Protocols, MEDVi, and Lilly Direct's self-pay Zepbound program exist.

Wegovy vs Zepbound vs compounded GLP-1 — how eligibility differs

The branded products and the compounded products live in different regulatory frames, and that affects the eligibility conversation. Wegovy and Zepbound are FDA-approved finished drug products with a labeled patient population, so the BMI threshold and comorbidity criteria are baked into the prescribing information — clinicians prescribe within the label by default. Compounded semaglutide and compounded tirzepatide are pharmacy-prepared formulations under U.S. compounding regulations; they are not FDA-approved finished drug products and have not been reviewed by the FDA for safety, effectiveness, or quality. Because compounded products don't carry an FDA-labeled patient population, eligibility decisions for compounded GLP-1s are made by the prescribing clinician on a per-patient basis. PlexusDx Weight Management Protocols use compounded semaglutide and compounded tirzepatide from licensed U.S. compounding pharmacies. PlexusDx does not enforce a hard BMI gate at the protocol level — the prescribing clinician evaluates each patient's BMI, medical history, comorbidities, contraindications, and goals during the intake, and prescribes only when clinical criteria are met. That clinician-driven evaluation is closer to how compounded GLP-1s are dispensed across the broader telehealth market than to a branded-pharmacy retail dispense.

BMI is a screening tool, not a diagnosis

BMI was designed as a population-level screening metric, and it has well-documented limitations at the individual level. It can mislead in muscular builds — a strength athlete with a high lean-mass ratio may register an "overweight" or "obese" BMI with a low body-fat percentage. It can mislead in older adults whose body composition has shifted toward a higher fat-to-lean ratio at lower body weights. Pregnancy and postpartum produce temporary weight changes that don't reflect baseline body composition. Edema and fluid retention from medical conditions affect weight without reflecting fat mass. Race and ethnicity can shift the relationship between BMI and metabolic risk — some Asian populations show metabolic risk at lower BMI thresholds than the standard cutoffs suggest. None of this invalidates the FDA-labeled BMI criteria for Wegovy and Zepbound — the labels are written using BMI specifically — but it explains why a thoughtful clinician will sometimes look at waist circumference, body composition, A1c, lipid panels, and blood pressure alongside the BMI number rather than treating the number as the whole picture. If you're borderline at BMI 26 or 27, that broader workup often determines whether a comorbidity is documented and whether the labeled criteria become applicable.

Where PlexusDx Weight Management Protocols fit

PlexusDx is cash-pay, no membership, all 50 states (5 require a scheduled live consultation rather than async intake), and uses licensed U.S. compounding pharmacies. Six protocols span the GLP-1 mechanism space. The Microdose GLP-1 Protocol is $129/mo flat with four delivery formats — capsule, troche, lozenge, and sublingual — designed for patients who want a low-cost entry point or a starter dose pathway. The Semaglutide Injection Protocol is $149/mo across five weekly dose levels (0.25mg to 2.0mg) and is the closest analogue in mechanism to Wegovy and Ozempic. The Tirzepatide Injection Protocol is $249/mo across six weekly dose levels (2.5mg to 15mg) and matches the GIP/GLP-1 dual-agonist mechanism of Zepbound and Mounjaro. The Semaglutide Oral Protocol is from $249/mo for patients who prefer a daily tablet format. The Tirzepatide Oral Protocol is $279/mo across seven daily dose levels. GLP-Squared is $249/mo and pairs compounded semaglutide with compounded tirzepatide for patients whose clinician determines a dual-compound approach is appropriate. Across all six protocols, BMI is one input the clinician evaluates — not a hard gate that rejects patients before clinical review.

Adding a genetic baseline before your first dose

BMI tells you about body composition relative to height. It says nothing about how your body will respond to a GLP-1 receptor agonist. GLP-1 response varies meaningfully across patients — variants in GLP1R, GIPR, FTO, MC4R, and TCF7L2 are associated with measurably different titration tolerability, weight-loss magnitude, and side-effect profiles for semaglutide and tirzepatide. The Precision Peptide Genetic Test ($298 standalone, or $99 as an add-on after your first month on any protocol) maps 48 genes and 57 variants across 14 health pathways — including 34 weight-management insights and the GIPR rs1800437 variant linked to differential GLP-1 response. The findings are delivered through the Peptide Pathways Report in the PlexusDx Results Portal so the prescribing clinician can use them when titrating. Eligibility based on BMI tells you whether a labeled medication category is on the table; a genetic baseline tells you whether a faster titration, a slower one, a tirzepatide-first approach, or a semaglutide-first approach is more likely to fit your biology before week one. The two questions answer different things, and a thoughtful weight-management plan considers both.

Frequently asked questions

What BMI do you need for Wegovy?

Wegovy's FDA label indicates a BMI of 30 or higher, or a BMI of 27–29.9 with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. The labeled threshold is the same threshold used in the STEP trials.

What BMI do you need for Zepbound?

Zepbound uses the same labeled threshold as Wegovy — BMI of 30 or higher, or BMI of 27–29.9 with at least one weight-related condition. Zepbound also carries a separate FDA indication for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial.

Is Zepbound approved for sleep apnea?

Yes. In late 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA Phase 3 results. This is a separate FDA indication from the chronic weight management indication and uses the obesity BMI threshold of 30 or higher.

Can I qualify with a BMI under 27?

For FDA-labeled chronic weight management indications, generally no — Wegovy, Zepbound, and Saxenda all start at BMI 27 with a comorbidity or BMI 30 without. Below BMI 27, the labeled weight-loss indications don't apply. PlexusDx Weight Management Protocols don't enforce a labeled BMI gate, but the prescribing clinician evaluates each patient's full clinical picture before prescribing.

Is compounded semaglutide the same as Wegovy?

No. Compounded semaglutide is a pharmacy-prepared formulation of the active ingredient and is not an FDA-approved finished drug product. The FDA has not reviewed compounded GLP-1s for safety, effectiveness, or quality. Wegovy is an FDA-approved finished product that ran the STEP trials. PlexusDx Semaglutide Injection Protocol uses compounded semaglutide from licensed U.S. compounding pharmacies, priced at $149/mo all-inclusive.

Does meeting BMI criteria guarantee insurance coverage?

No. Insurance plans frequently apply criteria stricter than FDA labeling, including higher BMI cutoffs, required documentation of prior weight-loss attempts, step therapy, or category-wide exclusions for anti-obesity medications. Meeting the FDA-labeled BMI threshold is necessary but not sufficient for insurance coverage. Cash-pay paths like PlexusDx Weight Management Protocols sidestep the insurance step entirely.

Is a BMI eligibility calculator medical advice?

No. A BMI calculator is an educational tool that estimates eligibility against publicly available FDA-labeled criteria. Only a licensed clinician can determine whether a specific GLP-1 medication is clinically appropriate for an individual patient. The clinician evaluates contraindications, drug interactions, comorbidities, and goals alongside BMI before prescribing.

GLP-1 BMI Eligibility (2026): Wegovy, Zepbound and PlexusDx | PlexusDx